How to Help Your Patients Save Money on Insulin Glargine: A Provider's Guide to Savings Programs

Despite historic insulin price reductions and expanded savings programs, medication affordability remains one of the top barriers to diabetes medication adherence in the United States. Patients who can't afford their Insulin Glargine ration doses, skip refills, or abandon therapy — with serious clinical consequences. This guide gives prescribers and their staff a comprehensive, actionable toolkit for reducing Insulin Glargine costs for every patient in 2026.

The Cost Landscape in 2026: Better Than Ever, But Still Confusing

The Insulin Glargine pricing landscape has improved dramatically since 2022. Key changes:

• Sanofi cut list prices 78% for Lantus and Toujeo in 2023–2024, reducing Lantus from ~$360/vial to ~$80–100/vial
• Sanofi Valyou Savings Program expanded to cover ALL U.S. patients at $35/month as of January 1, 2026 — including uninsured patients
• Medicare IRA cap: $35/month for all covered insulins under Medicare Part D, with no deductible phase
• Biosimilar competition: Multiple interchangeable biosimilars (Rezvoglar, Langlara, generic glargine) are now on market

Despite this progress, many patients still overpay because they don't know these programs exist or how to access them. That's where provider guidance makes a critical difference.

Savings Program Quick Reference by Patient Type

Commercially insured patients (employer insurance, ACA marketplace):

• Sanofi Insulins Co-pay Savings Program: caps Lantus/Toujeo at $35/month (up to 10 packs/fill, 12 fills/year)
• Eli Lilly $35/month program for Basaglar KwikPen and Rezvoglar
• State insulin copay caps apply in: Colorado, Illinois, Maine, New Mexico, Washington, and others ($25–100/month cap)

Uninsured patients:

• Sanofi Insulins Valyou Savings Program (IVSP): $35/month for Lantus/Toujeo — now available to uninsured patients as of January 1, 2026. Call 1-833-813-0190 or visit lantus.com.
• Sanofi Patient Connection: Free Lantus/Toujeo for income-qualifying patients (up to ~400% FPL). Apply at sanofipatientconnection.com.
• Lilly Cares Foundation: Free Basaglar/Rezvoglar for income-qualifying patients. Apply at lillycares.com.
• GoodRx, SingleCare: Generic insulin glargine as low as $54–75/vial; Lantus as low as $35 at some pharmacies
• 340B-eligible health centers: Significantly reduced prices for patients meeting eligibility criteria

Medicare Part D patients:

• $35/month cap under Inflation Reduction Act — permanent, no deductible phase, applies to all Medicare Part D plans
• Extra Help (LIS): Income-qualifying Medicare patients may pay even less
• Note: Medicare patients are NOT eligible for commercial manufacturer savings cards (Sanofi Valyou, Lilly programs)

Formulary and Prescribing Strategies to Reduce Patient Cost

Choosing the right insulin glargine product can significantly impact what your patient pays:

• Check formulary tier before prescribing — some plans prefer Basaglar (Eli Lilly) over Lantus; the preferred product often has a lower copay
• Consider prescribing vials instead of pens for patients without dexterity issues — vials are typically cheaper than pens, and U-100 vial pricing with GoodRx can be significantly lower
• For Semglee patients transitioning: Prescribe the plan's new preferred glargine product to avoid PA delays and higher copays
• Consider prescribing 90-day supplies — reduces frequency of pharmacist fees and often lowers per-unit cost

Integrating Savings Programs into Your Workflow

Practical ways to ensure patients access savings programs before they leave the office or pharmacy:

1. Include a savings program handout with every new Insulin Glargine prescription — simple one-pagers with QR codes to Sanofi and Lilly enrollment pages.
2. Train your MAs to ask at checkout: "Are you enrolled in the Sanofi Valyou savings program?" — a 30-second question that can save patients $300+ per year.
3. Use your EHR's e-prescribing platform to check real-time formulary and cost data at the point of prescribing.
4. Create a practice-level alert for Semglee patients needing transition Rx — issue new prescriptions proactively rather than waiting for patients to call when they run out.

The Role of medfinder for Provider Practices

When patients have a valid prescription but can't find the medication in stock at an affordable price, they often end up going without. medfinder's provider tools can help you direct patients to pharmacies near them that have their specific insulin glargine product — reducing the risk of missed doses due to access issues. Visit medfinder.com/providers to learn more.

Also see our Insulin Glargine shortage guide for providers for clinical and operational guidance on managing the 2026 market disruption.